• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC HEART VALVES DIVISION MOSAIC AORTIC BIOPROSTHETIC HEART VALVE; HEART-VALVE, REPLACEMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC HEART VALVES DIVISION MOSAIC AORTIC BIOPROSTHETIC HEART VALVE; HEART-VALVE, REPLACEMENT Back to Search Results
Model Number 30519
Device Problems Gradient Increase (1270); Inadequacy of Device Shape and/or Size (1583)
Patient Problems Atrial Fibrillation (1729); Endocarditis (1834); Myocardial Infarction (1969)
Event Date 11/17/2018
Event Type  Injury  
Manufacturer Narrative
Citation: braathen b et al.Trifecta has lower gradient and less prosthesis-patient mismatch than mosaic ultra in the aortic position: a prospective randomized study.J thorac cardiovasc surg.2019 oct;158(4):1032-1039.Doi: 10.1016/j.Jtcvs.2018.11.020.Epub 2018 nov 17.Earliest date of publish used for event date.No unique device identifier (serial/lot) numbers were provided; without this information it could not be determined whether these observations have been previously reported.Without return of the product no definitive conclusion can be made regarding the clinical observations.If information is provided in the future, a supplemental report will be issued.
 
Event Description
Medtronic received information via literature regarding a comparison of the hemodynamic profiles between the trifecta and mosaic ultra bioprosthetic surgical valves.All data were collected from a single center between september 2012 and november 2014.The study population included 90 patients and was predominantly male with a mean age of 77 years.Of those, 38 were implanted with medtronic mosaic ultra valves in the aortic position.No serial numbers were provided.Among all patients, 2 deaths occurred due to: cerebral stroke (1) and lung infection with renal failure (1).The type of valve (trifecta or mosaic ultra) that was used to treat these 2 patients was not reported.Based on the available information, medtronic product was not directly associated with the deaths.Among all patients, adverse events included: reoperation due to endocarditis, myocardial infarction, post-operative atrial fibrillation, high transvalvular gradients, and patient-prosthesis mismatch.Based on the available information, medtronic product may have been associated with the adverse events.No additional adverse patient effects or product performance issues were reported.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
MOSAIC AORTIC BIOPROSTHETIC HEART VALVE
Type of Device
HEART-VALVE, REPLACEMENT
Manufacturer (Section D)
MEDTRONIC HEART VALVES DIVISION
1851 e deere ave
santa ana CA 92705
Manufacturer (Section G)
MEDTRONIC HEART VALVES DIVISION
1851 e deere ave
santa ana CA 92705
Manufacturer Contact
paula bixby
8200 coral sea street ne
mounds view, MN 55112
7635055378
MDR Report Key9432009
MDR Text Key185009045
Report Number2025587-2019-03688
Device Sequence Number1
Product Code DYE
Combination Product (y/n)N
Reporter Country CodeNO
PMA/PMN Number
P990064
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,l
Reporter Occupation Physician
Type of Report Initial
Report Date 12/06/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received12/06/2019
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model Number30519
Device Catalogue Number30519
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received11/19/2019
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age77 YR
-
-